{"id":409277,"date":"2021-01-06T07:05:44","date_gmt":"2021-01-06T12:05:44","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=409277"},"modified":"2021-01-06T07:05:44","modified_gmt":"2021-01-06T12:05:44","slug":"marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/","title":{"rendered":"Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference<\/b><\/p>\n<p>RADNOR, Pa.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fmarinuspharma.com%2F&amp;esheet=52357040&amp;newsitemid=20210106005186&amp;lan=en-US&amp;anchor=Marinus+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=d0bdac395f4d57fbbc5aa09e5b3f2a70\">Marinus Pharmaceuticals, Inc.<\/a> (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that company management will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference. An audio-only presentation will take place January 14, 2021 at 3:40 pm EST. Company management will also participate in the H.C. Wainwright Bioconnect 2021 Conference on January 11.\n<\/p>\n<p>\nAdditional details can be found below:\n<\/p>\n<p><b>H.C. Wainwright Bioconnect 2021 Conference<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Date and Time: <\/b>On-demand starting Monday, January 11 6:00 am (EST)\n<\/li>\n<li><b>Speakers: <\/b>Scott Braunstein, M.D., Chief Executive Officer, Edward Smith, Chief Financial Officer, and Joseph Hulihan, M.D., Chief Medical Officer\n<\/li>\n<li><b>Webcast Link: <\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__journey.ct.events_view_4a598438-2Dedc8-2D41b3-2Dba58-2D04432ebd090b%26d%3DDwQGaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3DpAe08BGvGgzba9ymaErHMKGrZhIgsCMASlzRSrE25S0%26m%3DZjYOvvzGWlnXcVEUnF_kLco2JaFshXaYz5cR7sM-8KU%26s%3DJCcB1bLJajGDDrAF6sA5IT9fTTwNxPzTiib-pwM8ng0%26e%3D&amp;esheet=52357040&amp;newsitemid=20210106005186&amp;lan=en-US&amp;anchor=https%3A%2F%2Fjourney.ct.events%2Fview%2F4a598438-edc8-41b3-ba58-04432ebd090b&amp;index=2&amp;md5=ebc458a8526b9b6e30844cedb2349fcf\">https:\/\/journey.ct.events\/view\/4a598438-edc8-41b3-ba58-04432ebd090b<\/a><\/li>\n<\/ul>\n<p><b>39th Annual J.P. Morgan Healthcare Conference<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Date and Time: <\/b>Thursday, January 14 3:40 pm (EST)\n<\/li>\n<li><b>Speakers: <\/b>Scott Braunstein, M.D., Chief Executive Officer, Edward Smith, Chief Financial Officer, and Joseph Hulihan, M.D., Chief Medical Officer\n<\/li>\n<li><b>Audio Stream Link: <\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fjpmorgan.metameetings.net%2Fevents%2Fhealthcare21%2Fsessions%2F35731-marinus-pharmaceuticals-inc%2Fwebcast%3Fgpu_only%3Dtrue%26kiosk%3Dtrue&amp;esheet=52357040&amp;newsitemid=20210106005186&amp;lan=en-US&amp;anchor=https%3A%2F%2Fjpmorgan.metameetings.net%2Fevents%2Fhealthcare21%2Fsessions%2F35731-marinus-pharmaceuticals-inc%2Fwebcast%3Fgpu_only%3Dtrue%26amp%3Bkiosk%3Dtrue&amp;index=3&amp;md5=ee2f8643427c1504205caa270fafdd2f\">https:\/\/jpmorgan.metameetings.net\/events\/healthcare21\/sessions\/35731-marinus-pharmaceuticals-inc\/webcast?gpu_only=true&amp;kiosk=true<\/a><\/li>\n<\/ul>\n<p>\nWebcast and audio replays will be available following each event under the Investors &amp; Media page of the Company&#8217;s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.marinuspharma.com&amp;esheet=52357040&amp;newsitemid=20210106005186&amp;lan=en-US&amp;anchor=www.marinuspharma.com&amp;index=4&amp;md5=b1364f3ec0ce29d525291440b150e80e\">www.marinuspharma.com<\/a>.\n<\/p>\n<p><b>About Marinus Pharmaceuticals<\/b><\/p>\n<p>\nMarinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. The company intends to initiate a Phase 3 trial in status epilepticus. For more information visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.marinuspharma.com&amp;esheet=52357040&amp;newsitemid=20210106005186&amp;lan=en-US&amp;anchor=www.marinuspharma.com&amp;index=5&amp;md5=7448a642832cb65db02d67387a72b1e9\">www.marinuspharma.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210106005186r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210106005186\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210106005186\/en\/<\/a><\/span><\/p>\n<p>\nSasha Damouni Ellis<br \/>\n<br \/>Vice President, Investor Relations &amp; Corporate Communications<br \/>\n<br \/>Marinus Pharmaceuticals, Inc.<br \/>\n<br \/>484-253-6792\u00a0<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:sdamouni@marinuspharma.com\">sdamouni@marinuspharma.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Pennsylvania United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Finance Banking Clinical Trials Professional Services Biotechnology Health Pharmaceutical Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210106005186\/en\/809242\/3\/marinus-logo-2in.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference RADNOR, Pa.&#8211;(BUSINESS WIRE)&#8211;Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that company management will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference. An audio-only presentation will take place January 14, 2021 at 3:40 pm EST. Company management will also participate in the H.C. Wainwright Bioconnect 2021 Conference on January 11. Additional details can be found below: H.C. Wainwright Bioconnect 2021 Conference Date and Time: On-demand starting Monday, January 11 6:00 am (EST) Speakers: Scott Braunstein, M.D., Chief Executive Officer, Edward Smith, Chief Financial Officer, and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-409277","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference RADNOR, Pa.&#8211;(BUSINESS WIRE)&#8211;Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that company management will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference. An audio-only presentation will take place January 14, 2021 at 3:40 pm EST. Company management will also participate in the H.C. Wainwright Bioconnect 2021 Conference on January 11. Additional details can be found below: H.C. Wainwright Bioconnect 2021 Conference Date and Time: On-demand starting Monday, January 11 6:00 am (EST) Speakers: Scott Braunstein, M.D., Chief Executive Officer, Edward Smith, Chief Financial Officer, and &hellip; Continue reading &quot;Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-06T12:05:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210106005186r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference\",\"datePublished\":\"2021-01-06T12:05:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\\\/\"},\"wordCount\":422,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210106005186r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\\\/\",\"name\":\"Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210106005186r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-01-06T12:05:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210106005186r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210106005186r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/","og_locale":"en_US","og_type":"article","og_title":"Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference - Market Newsdesk","og_description":"Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference RADNOR, Pa.&#8211;(BUSINESS WIRE)&#8211;Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that company management will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference. An audio-only presentation will take place January 14, 2021 at 3:40 pm EST. Company management will also participate in the H.C. Wainwright Bioconnect 2021 Conference on January 11. Additional details can be found below: H.C. Wainwright Bioconnect 2021 Conference Date and Time: On-demand starting Monday, January 11 6:00 am (EST) Speakers: Scott Braunstein, M.D., Chief Executive Officer, Edward Smith, Chief Financial Officer, and &hellip; Continue reading \"Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-06T12:05:44+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210106005186r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference","datePublished":"2021-01-06T12:05:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/"},"wordCount":422,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210106005186r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/","name":"Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210106005186r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-01-06T12:05:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210106005186r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210106005186r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/marinus-pharmaceuticals-to-participate-in-39th-annual-j-p-morgan-healthcare-conference-and-the-h-c-wainwright-bioconnect-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=409277"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409277\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=409277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=409277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=409277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}